<DOC>
	<DOCNO>NCT00555230</DOCNO>
	<brief_summary>The purpose study : 1 . To evaluate prevalence preclinical atherosclerosis Chinese patient RA compare healthy control . 2 . To determine clinical biological measure best predict presence plaque increase arterial stiffness . 3 . To ascertain efficacy safety rosuvastatin prevention atherosclerosis patient RA measure carotid intima-media thickness ( IMT ) pulse wave velocity ( PWV ) .</brief_summary>
	<brief_title>Effects HMG-coA Reductase Inhibitor Rheumatoid Arthritis</brief_title>
	<detailed_description>150 consecutive RA patient follow Rheumatology clinic Prince Wales Hospital recruit double-blind , randomize , placebo-control trial . Patients match 150 control basis age ( within 5 year ) , sex , body mass index ( +/-5Kg ) ethnicity cross sectional study prevalence subclinical atherosclerosis . Controls healthy individual recruit community underwent similar imaging protocol IMT PWV assessment . Primary outcome improvement atherosclerosis Rosuvastatin therapy , evaluate IMT PWV . Secondary outcome : - Prevalence premature atherosclerosis RA patient compare healthy control term presence plague PWV . - Correlation clinical parameter , inflammatory marker ( CRP/hsCRP , TNF-alpha IL-6 ) atherosclerosis ( evaluated IMT , presence plaque PWV ) . - Relation among PWV , ABI AI RA patient , clinical significance combination . - Determine segment 's PWV good relation RA disease activity .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<mesh_term>Hydroxymethylglutaryl-CoA Reductase Inhibitors</mesh_term>
	<criteria>Men woman , 18 year age old Clinical diagnosis RA duration least 6 month Prednisolone &lt; =10 mg/day NSAID DMARD Informed consent Little ability selfcare Type 1 diabetes mellitus Uncontrolled hypertension ( &gt; 160/95 mmHg ) Total cholesterol &gt; 240 mg/dl , current recent ( within past 3 month ) History coronary bypass grafting , myocardial infraction within 28days , leave ventricular dysfunction ( ejection fraction &lt; 40 % ) , significant valvular heart disease Current treatment ACE inhibitor , angiotensin II receptor blocker betablockers , lipid lower drug , contraindication statin Current treatment oral contraceptive , estrogen progestin allow patient willing stop study Current treatment antioxidant therapy ( Vitamin C multivitamin ) Received intraarticular , intramuscular , intravenous corticosteroid past 4 week screen Clinically significant renal disease ( serum creatinine level ≥ 270 µmol/L ) aspartate aminotransferase ( AST ) , alanine aminotransferase ALT ) , creatine kinase ( CK ) ≥ 2 X ULN Female childbearing potential , unwilling use adequate contraception study Current recent ( within past 3 month ) pregnancy cancer</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2008</verification_date>
	<keyword>HMG-CoA reductase inhibitor</keyword>
	<keyword>Crestor</keyword>
	<keyword>Rosuvastatin</keyword>
</DOC>